Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 2,634

A recent discovery of a Gamma-ray burst (GRB) named GRB 220627A has left astronomers puzzled. GRBs are the most powerful explosions in the universe since the Big Bang, and typically last only seconds to a few minutes. However, GRB 220627A lasted for more than a thousand seconds, or just shy of 17 minutes, and arrived in two powerful bursts from an unknown event 2 billion years into the universe’s existence.

While the source of the burst appears to be ordinary, its length and double-burst nature have left astronomers puzzled. The likeliest explanation is that the GRB is the product of gravitational lensing, which is the warping of distant light sources by extremely massive objects such as galaxies and black holes. This would stretch, distort, and create echoes of the GRB’s signal before it arrived at Earth.

When a massive star runs out of fuel, it collapses before exploding outward in a gigantic supernova, leaving behind an ultra-dense neutron star or a black hole. It is these stellar explosions —and occasionally even collisions between two neutron stars — that produce powerful bursts of gamma rays that can be picked up by space observatories such as NASA’s Fermi Gamma-ray Space Telescope, which detected the new GRB.

Read more | >

But then Santamaria, who is at the University of Calgary in Canada, came up with a bold idea. Maybe he could use these particles as a therapy to target and quiet, or even kill, the cells responsible for driving the disease — those that destroy insulin-producing islet cells in the pancreas. It seemed like a far-fetched idea, but he decided to try it. “I kept doing experiment after experiment,” he says. Now, more than two decades later, Santamaria’s therapy is on the cusp of being tested in people.

It’s not alone. Researchers have been trying for more than 50 years to tame the cells that are responsible for autoimmune disorders such as type 1 diabetes, lupus and multiple sclerosis. Most of the approved therapies for these conditions work by suppressing the entire immune response. This often alleviates symptoms but leaves people at elevated risk of infections and cancers.

But for decades, immunologists have hoped to restore what’s known as tolerance — the immune system’s ability to ignore antigens that belong in the body while appropriately attacking those that don’t. In some cases, that means administering the very antigens that the rogue cells are trained to attack, a strategy that can deprogram the cells and dampen the autoimmune response. Other researchers are trying to selectively wipe out the problematic cells, or to introduce suppressive immune cells that have been engineered to target them. One approach that relies on engineered immune cells was used to treat 15 people with lupus or other immune disorders with surprising success1. One participant has been symptom-free for more than two and a half years.

Read more | >

Artificial intelligence (AI) has become an indispensable component in the analysis of microscopic data. However, while AI models are becoming better and more complex, the computing power and associated energy consumption are also increasing.

Researchers at the Leibniz-Institut für Analytische Wissenschaften (ISAS) and Peking University have therefore created a free compression software that allows scientists to run existing bioimaging AI models faster and with significantly lower .

The researchers have presented their user-friendly toolbox, called EfficientBioAI, in an article published in Nature Methods.

Read more | >